<DOC>
	<DOCNO>NCT00585312</DOCNO>
	<brief_summary>To test whether celecoxib use prevent colon polyp formation child familial adenomatous polyposis ( FAP ) .</brief_summary>
	<brief_title>Trial In Pediatric Patients With Familial Adenomatous Polyposis ( FAP )</brief_title>
	<detailed_description>Per DMC recommendation , study terminate early ( 31Oct2013 ) due low enrollment low endpoint accumulation rate . No safety concern involve decision terminate study .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Nasopharyngeal Neoplasms</mesh_term>
	<mesh_term>Adenomatous Polyposis Coli</mesh_term>
	<mesh_term>Celecoxib</mesh_term>
	<criteria>Age 1017 year Confirmed deleterious FAP genotype base central genetic test personal history ot &gt; 2 colorectal adenomas parent diagnosis FAP either A , B C A : Nonattenuated FAP genotype B : Attenuated FAP genotype personal history colorectal adenoma first degree relative FAP C : No genotype identify personal history &gt; 2 adenomas parent FAP Less 30 polyp , need remove render colon polypfree study drug give Diagnosis attenuate FAP base central genetic testing absence personal history &gt; 2 colorectal adenoma first degree relative ( parent sibling ) FAP . Sensitivity COX2 inhibitor</criteria>
	<gender>All</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>FAP</keyword>
</DOC>